Is deuterated coxitinib expensive to treat psoriasis?

Deucravacitinib as the first approved selectiveTYK2 inhibitor, has brought a new direction for the treatment of moderate to severe plaque psoriasis. Its application advantages are that it is convenient to take orally, highly targeted, and can improve skin plaques, itching and inflammatory reactions in clinical practice, while being well tolerated. Compared with traditional immunosuppressants and injectable biologics, this new drug provides patients with a more convenient and compliance option, and has therefore received great attention in the international market. As more real-world data accumulates, its application potential in immune diseases such as psoriasis will be further expanded.

Regarding the cost issue, the price of deuterated colexitinib varies greatly in different countries and regions. In China, the original version of the drug has been launched and has been included in medical insurance. The current price of 6 mg 7 tablets is around more than one thousand yuan. After medical insurance reimbursement, the financial burden on patients has been significantly reduced. In the US market, the price of 6 mg 30 tablets is as high as about 50,000 yuan. Affected by multiple factors such as the medical system and exchange rate, the price appears relatively expensive. For some economically underdeveloped areas, Laos and Bangladesh have officially launched generic versions. The price of 6mg*30 tablets is about four to five hundred yuan. Its drug ingredients are basically the same as the original drug, so it has become a feasible choice for some patients.

From the perspective of clinical value and cost comparison, although deuterated colexitinib is an innovative drug, with the support of medical insurance policies and the emergence of generic drugs, patient accessibility has greatly improved. Especially under the coverage of domestic medical insurance, patients no longer have to worry about high drug costs and can receive long-term and stable treatment. For a chronic disease like psoriasis, continuous and standardized treatment is far more important than short-term effects. Therefore, the gradual optimization of prices gives more patients the opportunity to achieve long-term control goals.

Reference materials:https://go.drugbank.com/drugs/DB16650